CO-RECEPTOR 8-AMPLIFYING (COR8:AMP™) TECHNOLOGY

Our technology features a synthetic fusion gene (coR8:Amp™) that comprises two genes- CD8a, a co-receptor for MHC class I molecule:peptide complex and MyD88, an intracellular signal transducer of innate immune response pathways. CD8a, enhances T cell binding to the cancer cell and TCR signaling while MyD88 amplifies TCR signals. Gene engineering of TILs with coR8:Amp construct results in increased efficacy, robust antitumor responses in various tumor models, and enhanced anti-tumor responses to various immune cell types (NK, TCR, CAR-T cells). coR8:Amp incorporation into TILs results in better and faster manufacturability due to faster expansion rates and retention of polyfunctional TILs, despite lower IL-2 concentrations during MightyTIL™ culture. Our composition of matter IP has issued in USA, Australia, and Japan and is pending in Europe and Canada.

Contact Us
Tech2.png
 

LEVERAGING COR8:AMP™ TECHNOLOGY TO GENERATE TILS WITH SUPERIOR PERFORMANCE CHARACTERISTICS

MightyTIL Chart.png